

Do Intestinal Microbiota and Thyroid Travel in Tandem?

Editorial

Giuseppe Merra^{1,*}, Annunziata Capacci², Antonino De Lorenzo¹, Laura Di Renzo¹, Paola Gualtieri¹, Maria Dri¹, Giulia Frank³, Marco Marchetti³

¹ Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy, E-mail: giuseppe.merra@uniroma2.it (GM).

² Department of Medical and Surgical Sciences, Agostino Gemelli General Hospital Foundation-IRCCS, Rome, Italy, E-mail: nunziacapacci@gmail.com.

³ School of Specialization in Food Science, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

***Corresponding author**

Giuseppe Merra,
Section of Clinical Nutrition &
Nutrigenomics, Department of
Biomedicine and Prevention,
University of Rome Tor Vergata,
00133 Rome, Italy.

Tel: +39-06-72596852,

E-Mail: giuseppe.merra@uniroma2.it.

Article Information

Received: 04-05-2022;

Accepted: 27-05-2022;

Published: 09-06-2022.

The gut microbiota exerts some pivotal metabolic functions in digestion and absorption of nutrients [1], detoxification and synthesis of vitamins [2]. Furthermore, it is essential in correct development of lymphoid tissue associated with intestine (GALT) [3], the largest component of the lymphoid system, which contains over 70% of the total immune system. Although the characterization of the "healthy microbiota" is not an easy task, the disruption of the homeostatic and mutualistic relationship between the gut microbiota and the host, called dysbiosis, is defined as "the altered composition and function in the microbiota are driven by a series of environmental and host-related factors, which perturb the microbial ecosystem to a greater extent than its capacity for resistance and resilience" [4]. The condition of dysbiosis, which can be linked to the excess of pathobionts, the reduction of the concentration of commensals and the microbial diversity [4] have been related to various gastrointestinal and systemic disorders, such as dysmetabolic diseases (obesity, type 2 diabetes mellitus) [5,6], allergic [7] (asthma), inflammatory [8] (IBD) and autoimmune. Among the latter, the most studied were type 1 diabetes mellitus [9], rheumatoid arthritis [10], multiple sclerosis [11], systemic lupus erythematosus [12] and Hashimoto's thyroiditis [13].

Effect of the microbiota on development and actions of the immune system.

The proper functioning of the immune system depends on the balance between tolerance towards auto-symbiotic bacteria and the correct targeting of the immune response against external harmful agents. The relationship between the host's immune system and microbiota is bidirectional: in fact, if the host's immune system is crucial for influencing the composition of gut microbiota, it has been shown that the microbial community could directly modulate innate and adaptive host immunity [14]. GF animals show impaired development of primary and

secondary lymphoid organs, a reduction in CD4 + and CD8 + T cells and an imbalance in the Th1 and Th2 differentiation pathway, in favor of the latter, evidenced by the overproduction of IL-4 and the reduction of IFN- γ production at the splenic level [15]. Most of these alterations can be reversed by colonization with the microflora of conventional animals. Studies conducted outside of mono-colonized animals have shown the specific role of some bacterial species in immunological imbalance. For example, the Th1 to Th2 imbalance was reversed by mono-colonization with *Bacteroides fragilis* due to the presence of the Polysaccharide A molecule [16]. In addition, GF mice show the absence of Th17 production in the small intestine, which can be restored by the presence of segmented filamentous bacteria (SBF); similarly, the concentration of regulatory T cells (Treg), which is reduced in the colon of GF mice, can be normalized by some colonization of *Clostridium* species [17]. Even the relationship between effector and regulatory lymphocyte concentrations appear to be controlled by the microbiota, through the production of SCFA and innate signals: rather, TLR9 and TLR5 knock-out mice show an increase in regulatory lymphocytes, associated with the reduced response of cytokine effector [18]. The microbiota is also involved in the activation and differentiation of B cells: although the total number of B cells in GF mice is comparable to that of conventional mice, fewer B cells in the small intestine, producing IgA and IgG1, can be detected and this condition can be restored to normal by the conventionalization of the flora [19]. Recently, the involvement of the microbiota in the differentiation of regulatory B cells (Breg) in the spleen and mesenteric lymphonoids has also been demonstrated [20].

Innate immunity is also influenced by the intestinal microbiota. The local and systemic concentration of metabolites produced by the microbiota seems to influence the development of the myeloid compartment in the bone marrow, guiding its

differentiation and functions, and the lymphoid arm of innate immunity with different mechanisms [21], as widely reviewed. In several animal models GF, macrophages and dendritic cells, as well as intestinal epithelial cells and ILC (innate lymphoid cells), both in their cytotoxic and non-cytotoxic subgroups, show alterations in number and/or function [22]. The microbiota has also been involved in the modulation of epigenetic changes in mammals: for example, through the production of diet-dependent (SCFA vitamins and polyamines) or independent (lipopolysaccharide and peptidoglycan) substances, the microflora is able to inhibit or activate enzymes, influencing the epigenetic state of whole organism. For example, SCFA has been shown to inhibit histone deacetylase, can reduce the production of interferon- γ [23] and increase naive CD4 + T cells and Treg cells [24].

Autoimmune disorders of the thyroid gland

Autoimmune thyroid disorders are the most common organ-specific autoimmune diseases, involving about 5% of the world population [25], with Hashimoto's thyroiditis (HT) being the most prevalent. Although the factors underlying the genesis of HT have not been fully clarified, it is now certain that the disease derives from the interaction of a predisposed genotype with endogenous and environmental triggers. The contribution of these problems in the pathophysiology of HT is not fully elucidated, but studies on sibling patients, as well as on monozygotic and dizygotic twins, support a relevant genetic influence on the development of the disease [26]. Environmental factors include: iodine consumption [27], the use of certain drugs, such as α -interferon [28], lithium [29] or immune checkpoint blocking molecules [30] and vitamin D deficiency [32]. A role of *Yersinia enterocolitica* and *Helicobacter pylori* infections have been hypothesized in the pathogenesis of thyroid autoimmunity, but only HCV infection, so far, has been associated with an increased risk for the development of Hashimoto's thyroiditis [32]. Among endogenous factors, female sex [33] and polymorphism of the vitamin D receptor gene are involved [34].

Studies on genetic predisposition have revealed that both thyroid-specific polymorphisms and immune-regulatory genes may be involved in the onset of autoimmune thyroid disease. Polymorphisms of single nucleotides of TSH receptor [35] and of the thyroglobulin molecule [36] have been associated with HT, as they can increase their self-antigenic potential or due to the variation of their expression at the thymic level, thus reducing central tolerance towards them. Concerning the immunoregulatory genes, alongside correlation with specific HLA class II haplotypes, which present antigens for recognition by CD4 + T helper cells, the involvement of CTLA-4 and PTPN-22 has been demonstrated [37]. These genes regulate certain characteristics of the immunological synapse, namely the presentation of the antigen, bound to HLA molecules, by presenting TCR antigen (T cell receptor) cells on T lymphocytes. Furthermore, the polymorphisms of IL2RA and FOXP3, genes pivotal in peripheral tolerance, mechanisms mediated by regulatory T lymphocytes, have been linked to the development of HT [38]. Recently, the hypothesis of post-transcriptional or post-translational events in the genesis of HT has been proposed: recent studies have focused on epigenetic modifications, such as methylation and histone modifications of DNA, as well as abnormal expression of microRNA and RNA long non-coding [39]. All these factors are actors in the regulation of gene expression, in turn involved in the maintenance of immune homeostasis [39].

The combined effect of environmental and genetic factors basically causes loss of tolerance towards self-antigens and determines the activation of T lymphocytes, which can undertake different differentiation paths, depending on the polarization of cytokines. Mainly involved in the genesis of HT are those characteristic pathways of the Th1 and Th17 effector, respectively involved in stimulation of cellular immunity and neutrophilic granulocytes [40]. However, when HT is concomitant with other autoimmune disorders, an increase in IL-4 percentage has also been described [41]. Additional elements of the immune system, involved in the genesis of thyroid autoimmunity, are represented by B and T cells, whose malfunction has been demonstrated in patients with HT [41]. The imbalance between anti- and pro-inflammatory effector cells is in favor of the latter, resulting in the collapse of self-tolerance and in direct attack from T lymphocytes to thyrocytes. Inflammation of the gland can result from the exposure of normally hidden antigens to which specific autoantibodies are produced, but not necessarily pathogens.

Intestine, microbiota and thyroid function:

The link between thyroid function and gastrointestinal system has been known for some time: T3 is considered one of the most important regulators of the development and differentiation of epithelial cells of the intestinal mucosa [42]. Clinically, the change in blood concentration of thyroid hormones is responsible for gastrointestinal symptoms, as evidenced by frequent gastrointestinal disturbances documented in the hypo- and hyper-function of the gland [43]. This effect may be due to the alteration of neuro-motor function of the gastrointestinal tract, which is expressed in different speed of propagation of the concentration in the musculature intestinal and in the possible edema of the muscular layer, due to the local infiltration of glycosaminoglycans [44]. Conversely, more recent studies have shown that changes in thyroid function may affect the intestinal microbial population. In particular, a study conducted in 2007 showed that, subjects with hypothyroidism have a greater chance of developing bacterial overgrowth of the small intestine. This can reach a concentration of microorganisms higher than 10⁶ CFU/mL of intestinal aspirate or colonic-type bacteria in the small intestine [45]. This excess of bacteria appears to contribute to impaired gastrointestinal neuromuscular function and consequent gastrointestinal symptoms complained of by patients: in fact, the decontamination obtained, through appropriate antibiotic therapy, led to the improvement of these symptoms [45]. Also hyperthyroidism seems contribute to intestinal dysbiosis [46], such as demonstrated by real-time PCR analysis, a significant reduction of *Bifidobacterium* e *Lactobacillus* and an increase in *Enterococcus* strains in fecal specimens from hyperthyroid subjects, than the euthyroid. Although this problem has been little studied, variations in the composition microbial have been shown to be responsible for changes in thyroid function. The analysis of the radioactive iodine uptake in GF or kanamycin-treated rats, compared to control population, revealed reduced thyroid function in GF rats [47]. A study conducted in 1996 also showed that TSH increased by 25% in GF mice, compared to those with normal intestinal flora [48]. Furthermore, intestinal flora seems to have a role in the recycling and enterohepatic metabolism of thyroid hormones [49]: in fact, both β -glucuronidase and sulfatase [50], which could lead to intestinal deconjugation and reabsorption of thyroid hormones in small

intestine. Some recent reports have suggested that intestine may also be involved in synthesis of endogenous compounds, such as thyronamine 3-T1AM, a decarboxylate derivative of thyroxine, and diiodothyronine 3.5T2, a derivative of triiodothyronine. The key enzymes for their production (isoforms deiodinase and ornithine decarboxylase), in fact, were detected in the wall of the murine intestine [51]. Based on their effects in animal models, has been hypothesized that they may also exert some of the non-genomic effects of thyroid hormones in humans [52]. Some species of microbial flora have been defined as "probiotics", according to their ability to contribute to microbial homeostasis [53]. Few studies have evaluated the effects of probiotic supplementation, reporting an increase in the thyroxine [54] and triiodothyronine [55] level in broilers. Furthermore, a study published in 2014 examined the beneficial effect of *Lactobacillus reuterii* on thyroid gland homeostasis in mice [56]. In fact, the supplemented mice showed a higher follicular epithelium and a greater mass of the thyroid gland, compared to the age-matched control group. Functionally, these mice showed higher levels of T4 in line with more active behavior and a slimmer shape. It is interesting to note that these beneficial effects on the mouse thyroid are mediated by the action of *Lactobacillus reuterii* on the production of interleukin-10 and the consequent enhancement of Treg cells: the effects of this integration, in fact, were no longer detectable in mice depleted in CD25+ [56].

Microbiota and thyroid autoimmunity

Similarly to other autoimmune disorders, attention to the link between microbial composition and thyroid autoimmunity has increased more and more. The involvement of dysbiosis in the genesis of inflammatory bowel disease has been well documented. Population variations of the gut microbiota have been reported in inflammatory [57] and autoimmune diseases, involving organs outside the gastrointestinal system. There are several mechanisms that link dysbiosis at the onset of autoimmune disease, such as molecular mimicry [58] from the activation of bystanders [59], and the spread of the epitheus [60]. These phenomena have been studied much more for diseases such as multiple sclerosis, rheumatoid arthritis, type 1 mellitus diabetes and systemic erythematosus lupus [61], but in recent years, alterations in the intestine microbial composition have also been reported in patients with Hashimoto's thyroiditis. Interestingly, ultrastructural morphological changes in enterocytes of distal duodenum were detected in HT patients [62]. In fact, a variation in the thickness of the microvilli and the increased space between adjacent microvilli were observed by examination with a transmission electron microscope [62]. In these patients, intestinal permeability was also assessed by a lactulose/mannitol test: a leaky intestinal condition was diagnosed in this category of patients, compared to the control group [62]. Since greater intestinal permeability allows the passage of toxins, antigens or bacterial metabolites from the intestine to the bloodstream, a role for this condition in the onset of autoimmune thyroid disease has been hypothesized [63].

The possible role of microbiota in influencing susceptibility to autoimmune thyroiditis has been demonstrated since 1988, where conventional and GF, genetically identical rats were compared: the administration of homogenized intestinal contents of conventionalized rats to GF animals increased their susceptibility to experimental autoimmune thyroiditis. This discovery suggested the importance of environmental

factors, namely the intestinal microbiota, in the pathogenesis of this disease [64]. It should be noted that, in an in vitro and in silico study, some components of specific strains of the genera *Bifidobacterium* and *Lactobacillus* share amino acid sequences with thyroid peroxidase and thyroglobulin and selectively bind human autoantibodies [65]. On the contrary, a study in mice has shown that daily ingestion of probiotics *Lactobacillus rhamnosus* HN001 and *Bifidobacterium Lactis* HN019 does not induce or help in the development of experimental autoimmune thyroiditis [66].

The implications on man:

The gut microbiota [67,68,69] shapes the thyroid mainly through the following microbial mechanisms:

- Dysbiosis damages the intestinal barrier and increases intestinal permeability, allowing antigens (molecules recognized as foreign by our immune system) to pass into circulation and activate the immune system;
- Circulating antibodies can react with the bacterial antigen and enhance the activation of inflammasome (the inflammasome is a cytoplasmic intracellular signaling multiprotein complex which is known as a mediator of innate immunity, i.e. of that natural immunity not specific that is present from birth and is the body's first immune defense barrier, responsible for the inflammatory response to infections and diseases) in the thyroid gland. Some scientists demonstrated that the expression of the inflammasome in patients with Hashimoto's thyroiditis was significantly increased and that it can be regulated by the intestinal microbiota and its metabolism;
- Short-chain fatty acids (SCFA), metabolites of the fermentation of commensal bacteria in dietary fiber, are hypothesized to play a crucial role in development, functioning and modulation of immune system.

Recently, many researchers [70,71,72,73] have observed that patients with Autoimmune Thyroid Disease (AITD) have a reduction in the so-called α diversity (diversity that takes into account the number of species in a more or less uniform small area) and an abundance of some microorganisms compared to the patients considered who were not affected by AITD. Furthermore, the current results have revealed the correlation between the clinical parameters of AITD, such as TRAb (Anti TSH Receptor) or TPOAb (Anti-thyroid peroxidase antibodies) and the microbiota.

For example:

- Some researchers found that the proportion of Synergistetes (a phylum of anaerobic bacteria) was negatively correlated with TRAb;
- Other researchers found that the *Lactobacillus* genus of bacteria was positively correlated with TRAb;
- Regarding the phylum (i.e. the type), some researchers found a higher ratio of intestinal bacteria.

Firmicutes/Bacteroidetes in patients with Graves'disease (GD) than in the control group, which may be relevant for inflammatory disease; while other researchers found that the ratio was significantly decreased in AITD patients.

To better understand the potential role of the gut microbiota in pathogenesis of Autoimmune Thyroid Disease, a meta-analysis70

was performed to evaluate the alteration in the microbial population between patients with Autoimmune Thyroid Disease and healthy controls (i.e. people who did not have autoimmune thyroid disease).

Thanks to the development of 16S ribosomal RNA gene sequencing technologies, significant alterations in the abundance and composition of the gut microbiota have been found between AITD and healthy controls, suggesting that the gut-thyroid axis may play a pivotal role in the development and in the progress of the AITD.

Although Hashimoto's thyroiditis (HT) and Graves' disease (GD) [74,75] are considered the two most common forms of Autoimmune Thyroid Disease (AITD), the pathogenesis and hallmark of Hashimoto's and Graves' disease are quite different. The hallmark of Hashimoto's thyroiditis is the high rate of Ab-TPO and Ab-TG, while the hallmark of Graves' disease is a high level of Ab-TR.

Furthermore, the alteration of some compositions of the intestinal microbiota can be different in Hashimoto's thyroiditis and Graves' disease. For example, the richness species index was significantly elevated in samples from patients with Hashimoto's thyroiditis while it was low in patients with Graves' disease. Richness species is an important feature of ecological composition and structure of microbial community.

Autoimmune Thyroid Disease is linked to intestinal microbiota dysbiosis through several mechanisms, such as: bacterial overgrowth, hyperactivation of the inflammasome, increase in intestinal permeability, alteration of microbiota metabolites and immune homeostasis. However, the mechanisms of the gut-thyroid axis [76,77] complex have not been fully elucidated.

Firmicutes and Bacteroidetes are the main microorganisms that predominate as regards, from a taxonomic point of view, the type. Traditionally, the relationship between Firmicutes and Bacteroidetes has been implicated in the predisposition of pathological conditions. In this meta-analysis, the relationship of Firmicutes and Bacteroidetes in patients with Autoimmune Thyroid Disease showed a lower level than their healthy counterparts.

Furthermore, patients with Autoimmune Thyroid Disease (AITD) showed a noticeable alteration in composition of gut microbiota compared to controls. A 'random effect model' indicates that people with AITD showed a significantly increased relative abundance of pathogenic bacteria and a reduced percentage of beneficial bacteria such as *Lactobacillus* and *Bifidobacterium*. The latter could be used as probiotics to modulate immune response without negative effects on development of an experimental mouse model of autoimmune thyroiditis [78]. Furthermore, *Lactobacillus* has been shown to protect TH17 cells and support the integrity of the barrier by secreting IL-22 cytokines and pro-inflammatory IL-17 cytokine. The Th17/Treg imbalance can cause inflammatory disorders, indicating that *Lactobacillus* participates in the balance of the immune system. Overall, *Bifidobacterium* and *Lactobacillus* have shown anti-inflammatory effects and protect our body from pathogens.

Furthermore, the increase in *Bacteroides fragilis* species can explain the upregulation of the IL-18 cytokine, IL-1 β and caspase-1 by promoting the inflammatory response. Furthermore, *B. fragilis* can activate the expression of the NLRP3 inflammasome, which has

been found to be over-expressed in patients with Hashimoto's thyroiditis. However, the interaction between intestinal microbiota and inflammasome is not yet clear.

In conclusion, there is a reciprocal influence between the microbiota composition and thyroid homeostasis [79], but the evidence still emerges only from animal studies, in humans this has not been fully characterized.

Another reasonable hypothesis of the role that the microbiota plays in the advancement of AITD is molecular mimicry. The antigenic properties of the proteins of some intestinal bacteria can bind Ab-TPO and Ab-TG, which are the main clinical diagnostic parameters of Autoimmune Thyroid Disease.

References:

1. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr.* 2018 Feb;57(1):1-24. doi: 10.1007/s00394-017-1445-8. Epub 2017 Apr 9. PMID: 28393285; PMCID: PMC5847071.
2. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol.* 2013 Apr;24(2):160-8. doi: 10.1016/j.copbio.2012.08.005. Epub 2012 Aug 30. PMID: 22940212.
3. Suzuki K, Kawamoto S, Maruya M, Fagarasan S. GALT: organization and dynamics leading to IgA synthesis. *Adv Immunol.* 2010;107:153-85. doi: 10.1016/B978-0-12-381300-8.00006-X. PMID: 21034974.
4. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. *Nat Rev Immunol.* 2017 Apr;17(4):219-232. doi: 10.1038/nri.2017.7. Epub 2017 Mar 6. PMID: 28260787.
5. Arora T, Bäckhed F. The gut microbiota and metabolic disease: current understanding and future perspectives. *J Intern Med.* 2016 Oct;280(4):339-49. doi: 10.1111/joim.12508. Epub 2016 Apr 12. PMID: 27071815.
6. Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. *Pharmacogenomics J.* 2013 Dec;13(6):514-22. doi: 10.1038/tpj.2012.43. Epub 2012 Oct 2. PMID: 23032991.
7. Rothenberg ME, Saito H, Peebles RS Jr. Advances in mechanisms of allergic disease in 2016. *J Allergy Clin Immunol.* 2017 Dec;140(6):1622-1631. doi: 10.1016/j.jaci.2017.08.029. Epub 2017 Oct 13. PMID: 29038009.
8. McIlroy J, Ianiro G, Mukhopadhyaya I, Hansen R, Hold GL. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. *Aliment Pharmacol Ther.* 2018 Jan;47(1):26-42. doi: 10.1111/apt.14384. Epub 2017 Oct 16. PMID: 29034981.
9. Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, Lernmark Å, Rewers M, Hagopian W, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer J, Norris JM, Virtanen SM; TEDDY Study Group. Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. *JAMA Pediatr.* 2016 Jan;170(1):20-8. doi: 10.1001/jamapediatrics.2015.2757. PMID: 26552054; PMCID: PMC4803028.

10. Pianta A, Arvikar SL, Strle K, Drouin EE, Wang Q, Costello CE, Steere AC. Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. *J Clin Invest*. 2017 Aug 1;127(8):2946-2956. doi: 10.1172/JCI93450. Epub 2017 Jun 26. PMID: 28650341; PMCID: PMC5531397.
11. Montassier E, Berthelot L, Soullilou JP. Are the decrease in circulating anti- α 1,3-Gal IgG and the lower content of galactosyl transferase A1 in the microbiota of patients with multiple sclerosis a novel environmental risk factor for the disease? *Mol Immunol*. 2018 Jan;93:162-165. doi: 10.1016/j.molimm.2017.09.016. Epub 2017 Nov 28. PMID: 29195140.
12. Hevia A, Milani C, López P, Cuervo A, Arboleya S, Duranti S, Turróni F, González S, Suárez A, Gueimonde M, Ventura M, Sánchez B, Margolles A. Intestinal dysbiosis associated with systemic lupus erythematosus. *mBio*. 2014 Sep 30;5(5):e01548-14. doi: 10.1128/mBio.01548-14. PMID: 25271284; PMCID: PMC4196225.
13. Virili C, Fallahi P, Antonelli A, Benvenga S, Centanni M. Gut microbiota and Hashimoto's thyroiditis. *Rev Endocr Metab Disord*. 2018 Dec;19(4):293-300. doi: 10.1007/s11154-018-9467-y. PMID: 30294759.
14. Chow J, Lee SM, Shen Y, Khosravi A, Mazmanian SK. Host-bacterial symbiosis in health and disease. *Adv Immunol*. 2010;107:243-74. doi: 10.1016/B978-0-12-381300-8.00008-3. PMID: 21034976; PMCID: PMC3152488.
15. Macpherson GR, Figg WD. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. *Cancer Biol Ther*. 2004 Jun;3(6):503-4. doi: 10.4161/cbt.3.6.961. Epub 2004 Jun 10. PMID: 15197355.
16. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*. 2005 Jul 15;122(1):107-18. doi: 10.1016/j.cell.2005.05.007. PMID: 16009137.
17. Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM, Burzyn D, Ortiz-Lopez A, Lobera M, Yang J, Ghosh S, Earl A, Snapper SB, Jupp R, Kasper D, Mathis D, Benoist C. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of ROR γ ⁺ regulatory T cells. *Science*. 2015 Aug 28;349(6251):993-7. doi: 10.1126/science.aaa9420. Epub 2015 Aug 13. PMID: 26272906; PMCID: PMC4700932.
18. Hall HT, Wilhelm MT, Saibil SD, Mak TW, Flavell RA, Ohashi PS. RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses. *Eur J Immunol*. 2008 Jan;38(1):64-72. doi: 10.1002/eji.200737393. PMID: 18085666.
19. Yurkovetskiy LA, Pickard JM, Chervonsky AV. Microbiota and autoimmunity: exploring new avenues. *Cell Host Microbe*. 2015 May 13;17(5):548-52. doi: 10.1016/j.chom.2015.04.010. PMID: 25974297; PMCID: PMC4535992.
20. Rosser EC, Blair PA, Mauri C. Cellular targets of regulatory B cell-mediated suppression. *Mol Immunol*. 2014 Dec;62(2):296-304. doi: 10.1016/j.molimm.2014.01.014. Epub 2014 Feb 18. PMID: 24556109.
21. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature*. 2016 Jul 7;535(7610):65-74. doi: 10.1038/nature18847. PMID: 27383981.
22. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012 Jan-Feb;3(1):4-14. doi: 10.4161/gmic.19320. Epub 2012 Jan 1. PMID: 22356853; PMCID: PMC3337124.
23. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther*. 2008 Jan 15;27(2):104-19. doi: 10.1111/j.1365-2036.2007.03562.x. Epub 2007 Oct 25. PMID: 17973645.
24. Alenghat T, Artis D. Epigenomic regulation of host-microbiota interactions. *Trends Immunol*. 2014 Nov;35(11):518-25. doi: 10.1016/j.it.2014.09.007. Epub 2014 Oct 22. PMID: 25443494; PMCID: PMC4254645.
25. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. *Autoimmun Rev*. 2015 Feb;14(2):174-80. doi: 10.1016/j.autrev.2014.10.016. Epub 2014 Oct 25. PMID: 25461470.
26. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. *Annu Rev Pathol*. 2014;9:147-56. doi: 10.1146/annurev-pathol-012513-104713. PMID: 24460189; PMCID: PMC4128637.
27. Latrofa F, Fiore E, Rago T, Antonangeli L, Montanelli L, Ricci D, Provenzale MA, Scutari M, Frigeri M, Tonacchera M, Vitti P. Iodine contributes to thyroid autoimmunity in humans by unmasking a cryptic epitope on thyroglobulin. *J Clin Endocrinol Metab*. 2013 Nov;98(11):E1768-74. doi: 10.1210/jc.2013-2912. Epub 2013 Sep 24. PMID: 24064687.
28. Obołończyk Ł, Siekierska-Hellmann M, Wiśniewski P, Lewczuk A, Berendt-Obołończyk M, Lakomy A, Michalska Z, Radowska D, Moszkowska G, Bianek-Bodzak A, Sworczak K. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study. *Postepy Hig Med Dosw (Online)*. 2017 Sep 25;71(0):842-849. doi: 10.5604/01.3001.0010.4782. PMID: 29039351.
29. Dineen R, Bogdanet D, Thompson D, Thompson CJ, Behan LA, McKay AP, Boran G, Wall C, Gibney J, O'Keane V, Sherlock M. Endocrinopathies and renal outcomes in lithium therapy: impact of lithium toxicity. *QJM*. 2017 Dec 1;110(12):821-827. doi: 10.1093/qjmed/hcx171. PMID: 29590494.
30. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. *J Thorac Dis*. 2018 Feb;10(Suppl 3):S480-S489. doi: 10.21037/jtd.2018.01.111. PMID: 29593893; PMCID: PMC5861268.
31. Wang J, Zhou JJ, Robertson GR, Lee VW. Vitamin D in Vascular Calcification: A Double-Edged Sword? *Nutrients*. 2018 May 22;10(5):652. doi: 10.3390/nu10050652. PMID: 29786640; PMCID: PMC5986531.
32. Tomer Y. Hepatitis C. Interferon induced thyroiditis. *J Autoimmun*. 2010 May;34(3):J322-6. doi: 10.1016/j.jaut.2009.11.008. PMID: 20022216; PMCID: PMC2835812.
33. Fish SA, Langer JE, Mandel SJ. Sonographic imaging of thyroid nodules and cervical lymph nodes. *Endocrinol Metab Clin North Am*. 2008 Jun;37(2):401-17, ix. doi: 10.1016/j.ecl.2007.12.003. PMID: 18502334.

34. Feng M, Li H, Chen SF, Li WF, Zhang FB. Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases: a meta-analysis. *Endocrine*. 2013 Apr;43(2):318-26. doi: 10.1007/s12020-012-9812-y. Epub 2012 Oct 12. PMID: 23065592.
35. Fujii T, Mashimo M, Moriwaki Y, Misawa H, Ono S, Horiguchi K, Kawashima K. Expression and Function of the Cholinergic System in Immune Cells. *Front Immunol*. 2017 Sep 6;8:1085. doi: 10.3389/fimmu.2017.01085. PMID: 28932225; PMCID: PMC5592202.
36. Mizuma T, Watanabe M, Inoue N, Arakawa Y, Tomari S, Hidaka Y, Iwatani Y. Association of the polymorphisms in the gene encoding thyroglobulin with the development and prognosis of autoimmune thyroid disease. *Autoimmunity*. 2017 Sep;50(6):386-392. doi: 10.1080/08916934.2017.1344971. Epub 2017 Jul 4. PMID: 28675712.
37. Dultz G, Matheis N, Dittmar M, Bender K, Kahaly GJ. CTLA-4 CT60 polymorphism in thyroid and polyglandular autoimmunity. *Horm Metab Res*. 2009 Jun;41(6):426-9. doi: 10.1055/s-0029-1214414. PMID: 19530270.
38. Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. *J Autoimmun*. 2015 Nov;64:82-90. doi: 10.1016/j.jaut.2015.07.009. Epub 2015 Jul 30. PMID: 26235382; PMCID: PMC4628844.
39. Wang B, Shao X, Song R, Xu D, Zhang JA. The Emerging Role of Epigenetics in Autoimmune Thyroid Diseases. *Front Immunol*. 2017 Apr 7;8:396. doi: 10.3389/fimmu.2017.00396. PMID: 28439272; PMCID: PMC5383710.
40. Shi Y, Wang H, Su Z, Chen J, Xue Y, Wang S, Xue Y, He Z, Yang H, Zhou C, Kong F, Liu Y, Yang P, Lu L, Shao Q, Huang X, Xu H. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto's thyroiditis. *Scand J Immunol*. 2010 Sep;72(3):250-5. doi: 10.1111/j.1365-3083.2010.02425.x. PMID: 20696023.
41. Santaguida MG, Nardo S, Del Duca SC, Lococo E, Virili C, Gargano L, Lenti L, Centanni M. Increased interleukin-4-positive lymphocytes in patients with Hashimoto's thyroiditis and concurrent non-endocrine autoimmune disorders. *Clin Exp Immunol*. 2011 Aug;165(2):148-54. doi: 10.1111/j.1365-2249.2011.04419.x. Epub 2011 May 30. PMID: 21623768; PMCID: PMC3142639.
42. Meng S, Badrinarain J, Sibley E, Fang R, Hodin R. Thyroid hormone and the d-type cyclins interact in regulating enterocyte gene transcription. *J Gastrointest Surg*. 2001 Jan-Feb;5(1):49-55. doi: 10.1016/s1091-255x(01)80013-5. PMID: 11309648.
43. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. *Endocrinol Metab Clin North Am*. 2007 Sep;36(3):595-615, v. doi: 10.1016/j.ecl.2007.04.008. PMID: 17673121.
44. Daher R, Yazbeck T, Jaoude JB, Abboud B. Consequences of dysthyroidism on the digestive tract and viscera. *World J Gastroenterol*. 2009 Jun 21;15(23):2834-8. doi: 10.3748/wjg.15.2834. PMID: 19533804; PMCID: PMC2699000.
45. Lauritano EC, Bilotta AL, Gabrielli M, Scarpellini E, Lupascu A, Laginestra A, Novi M, Sottili S, Serricchio M, Cammarota G, Gasbarrini G, Pontecorvi A, Gasbarrini A. Association between hypothyroidism and small intestinal bacterial overgrowth. *J Clin Endocrinol Metab*. 2007 Nov;92(11):4180-4. doi: 10.1210/jc.2007-0606. Epub 2007 Aug 14. PMID: 17698907.
46. Zhou L, Li X, Ahmed A, Wu D, Liu L, Qiu J, Yan Y, Jin M, Xin Y. Gut microbe analysis between hyperthyroid and healthy individuals. *Curr Microbiol*. 2014 Nov;69(5):675-80. doi: 10.1007/s00284-014-0640-6. Epub 2014 Jun 27. PMID: 24969306.
47. Vought RL, Brown FA, Sibinovic KH, McDaniel EG. Effect of changing intestinal bacterial flora on thyroid function in the rat. *Horm Metab Res*. 1972 Jan;4(1):43-7. doi: 10.1055/s-0028-1094095. PMID: 4110893.
48. Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. *FEMS Microbiol Rev*. 2015 Jul;39(4):509-21. doi: 10.1093/femsre/fuu010. Epub 2015 Feb 19. PMID: 25701044.
49. Virili C, Centanni M. "With a little help from my friends" - The role of microbiota in thyroid hormone metabolism and enterohepatic recycling. *Mol Cell Endocrinol*. 2017 Dec 15;458:39-43. doi: 10.1016/j.mce.2017.01.053. Epub 2017 Feb 4. PMID: 28167127.
50. de Herder WW, Hazenberg MP, Pennock-Schröder AM, Hennemann G, Visser TJ. Rapid and bacteria-dependent in vitro hydrolysis of iodothyronine-conjugates by intestinal contents of humans and rats. *Med Biol*. 1986;64(1):31-5. PMID: 3724259.
51. Hoefig CS, Jacobi SF, Warner A, Harder L, Schanze N, Vennström B, Mittag J. 3-Iodothyroacetic acid lacks thermoregulatory and cardiovascular effects in vivo. *Br J Pharmacol*. 2015 Jul;172(13):3426-33. doi: 10.1111/bph.13131. Epub 2015 Jun 9. PMID: 25765843; PMCID: PMC4500376.
52. Hoefig CS, Zucchi R, Köhrle J. Thyronamines and Derivatives: Physiological Relevance, Pharmacological Actions, and Future Research Directions. *Thyroid*. 2016 Dec;26(12):1656-1673. doi: 10.1089/thy.2016.0178. Epub 2016 Nov 9. PMID: 27650974.
53. Tannock GW. Can the gut microflora of infants be modified by giving probiotics to mothers? *J Pediatr Gastroenterol Nutr*. 2004 Mar;38(3):244-6. doi: 10.1097/00005176-200403000-00004. PMID: 15076621.
54. Sohail MU, Ijaz A, Yousaf MS, Ashraf K, Zaneb H, Aleem M, Rehman H. Alleviation of cyclic heat stress in broilers by dietary supplementation of mannan-oligosaccharide and Lactobacillus-based probiotic: dynamics of cortisol, thyroid hormones, cholesterol, C-reactive protein, and humoral immunity. *Poult Sci*. 2010 Sep;89(9):1934-8. doi: 10.3382/ps.2010-00751. PMID: 20709978.
55. Chotinsky D, Toncheva E, Profirov Y. Development of disaccharidase activity in the small intestine of broiler chickens. *Br Poult Sci*. 2001 Jul;42(3):389-93. doi: 10.1080/00071660120055386. PMID: 11469561.
56. Varian BJ, Poutahidis T, Levkovich T, Ibrahim YM, Lakritz JR, et al. (2014) Beneficial Bacteria Stimulate Youthful Thyroid Gland Activity. *J Obes Weight Loss Ther* 4:220. doi:10.4172/2165-7904.1000220

57. Garn H, Bahn S, Baune BT, Binder EB, Bisgaard H, Chatila TA, Chavakis T, Culmsee C, Dannowski U, Gay S, Gern J, Haahtela T, Kircher T, Müller-Ladner U, Neurath MF, Preissner KT, Reinhardt C, Rook G, Russell S, Schmeck B, Stappenbeck T, Steinhoff U, van Os J, Weiss S, Zemlin M, Renz H. Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation. *J Allergy Clin Immunol*. 2016 Jul;138(1):47-56. doi: 10.1016/j.jaci.2016.02.046. PMID: 27373325.
58. Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. *Rev Endocr Metab Disord*. 2016 Dec;17(4):485-498. doi: 10.1007/s11154-016-9363-2. PMID: 27307072.
59. Arata N, Ando T, Unger P, Davies TF. By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. *Clin Immunol*. 2006 Oct;121(1):108-17. doi: 10.1016/j.clim.2006.03.011. Epub 2006 Aug 17. PMID: 16916620.
60. Thrasyvoulides A, Lymberi P. Evidence for intramolecular B-cell epitope spreading during experimental immunization with an immunogenic thyroglobulin peptide. *Clin Exp Immunol*. 2003 Jun;132(3):401-7. doi: 10.1046/j.1365-2249.2003.02162.x. PMID: 12780685; PMCID: PMC1808729.
61. de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. Intestinal dysbiosis and probiotic applications in autoimmune diseases. *Immunology*. 2017 Sep;152(1):1-12. doi: 10.1111/imm.12765. Epub 2017 Jun 29. PMID: 28556916; PMCID: PMC5543467.
62. Sasso FC, Carbonara O, Torella R, Mezzogiorno A, Esposito V, Demagistris L, Secondulfo M, Carratu' R, Iafusco D, Carteni M. Ultrastructural changes in enterocytes in subjects with Hashimoto's thyroiditis. *Gut*. 2004 Dec;53(12):1878-80. doi: 10.1136/gut.2004.047498. PMID: 15542532; PMCID: PMC1774342.
63. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky Gut As a Danger Signal for Autoimmune Diseases. *Front Immunol*. 2017 May 23;8:598. doi: 10.3389/fimmu.2017.00598. PMID: 28588585; PMCID: PMC5440529.
64. Penhale WJ, Young PR. The influence of the normal microbial flora on the susceptibility of rats to experimental autoimmune thyroiditis. *Clin Exp Immunol*. 1988 May;72(2):288-92. PMID: 2970354; PMCID: PMC1541533.
65. Kiseleva EP, Mikhailopulo KI, Sviridov OV, Novik GI, Knirel YA, Szwajcer Dey E. The role of components of Bifidobacterium and Lactobacillus in pathogenesis and serologic diagnosis of autoimmune thyroid diseases. *Benef Microbes*. 2011 Jun;2(2):139-54. doi: 10.3920/BM2010.0011. PMID: 21831795.
66. Zhou JS, Gill HS. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. *Int J Food Microbiol*. 2005 Aug 15;103(1):97-104. doi: 10.1016/j.ijfoodmicro.2004.11.031. PMID: 16084270.
67. Romano L, De Santis GL, Gualtieri P, Merra G. Thyroid disorders and Mediterranean diet: which way to prevent metabolic complications. *Eur Rev Med Pharmacol Sci*. 2017 Aug;21(16):3531-3532. PMID: 28925494.
68. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, De Lorenzo A. Influence of Mediterranean Diet on Human Gut Microbiota. *Nutrients*. 2020 Dec 22;13(1):7. doi: 10.3390/nu13010007. PMID: 33375042; PMCID: PMC7822000.
69. Merra G, Capacci A, Cennamo G, Esposito E, Dri M, Di Renzo L, Marchetti M. The "Microbiome": A Protagonist in COVID-19 Era. *Microorganisms*. 2022 Jan 26;10(2):296. doi: 10.3390/microorganisms10020296. PMID: 35208751; PMCID: PMC8879283.
70. Gong B, Wang C, Meng F, Wang H, Song B, Yang Y, Shan Z. Association Between Gut Microbiota and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*. 2021 Nov 17;12:774362. doi: 10.3389/fendo.2021.774362. PMID: 34867823; PMCID: PMC8635774.
71. Belkaid Y and Harrison OJ. Homeostatic immunity and the microbiota. *Immunity* 2017 Apr 18;46(4):562-576.
72. Docimo G et al. The human microbiota in endocrinology: implications for pathophysiology, treatment and prognosis in thyroid diseases. *Front Endocrinol* 2020 Dec 4;11:586529.
73. Frohlich E and Wahl R. Microbiota and thyroid interactions in health and disease. *Trends Endocrinol Metab* 2019 Aug;30(8):479-490.
74. Jiang W et al. Gut microbiota may play a significant role in pathogenesis of Grave's disease. *Thyroid* 2021 May;31(5):810-820.
75. Mori K. et al. Does the gut microbiota trigger Hashimoto's Thyroiditis? *Discov Med* 2012;14(78):321-6.
76. Knezevic J et al. Thyroid-gut-axis: how does the microbiota influence thyroid function? *Nutrients* 2020 Jun 12;12(6):1769.
77. Su X et al. Gut dysbiosis is associated with primary hypothyroidism with interation on gut-tyroid axis. *Clin Sci (Lond)* 2020 Jun 26;134(12):1521-1535.
78. Shin NR et al. Chemically or surgically induced thyroid dysfunction altered gut microbiota in rat models. *FASEB J* 2020 Jun;34(6):8686-8701.
79. Virili C and Centanni M. Does microbiota composition affect thyroid homeostasis? *Endocrine* 2015;49:583-587.

Citation: Merra G, Capacci A, De Lorenzo A, et al; Do Intestinal Microbiota and Thyroid Travel in Tandem? *Medp Nutr Food Sci*. 2022; 1(1): mpnfs-202205001.